Rituximab +/- Ibruitinib

Protocol Number: The USOncologyNetwork – 16176 (www.clinicaltrials.gov)
A Multicenter, Randomized, Double-blind Placebo-controlled Phase 3 Study of Bruton’s Tyrosine Kinas (BTK) Inhibitor, Ibrutinib, in Combination with Rituximb versus Placebo in Combination with Rituximab in Treatment Naïve Subjects with Follicular Lymphoma